Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GZR18 in Participants With Obesity or Overweight
NCT06737042Phase 2Completed
- Sponsor
- Gan & Lee Pharmaceuticals
- Start
- Feb 2025
- Primary completion
- Feb 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bofanglutide in obesity (4 arms), sponsored by Gan & Lee Pharmaceuticals. Primary endpoint: Primary Objective at 36 weeks. Started Feb 2025; status: completed.
02
Drugs
bofanglutide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06737042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06737042.